High risk of hypogonadism in young male cancer survivors

Summary

Objective

Cancer and its treatment in childhood and young adulthood can cause hypogonadism, leading to increased risk of long term morbidity and mortality. The aim of this study was to evaluate the risk of presenting with biochemical signs of hypogonadism in testicular cancer survivors (TCS) and male childhood cancer survivors (CCS) in relation to the type of treatment given.

Design

Case-control study.

Patients

Ninety-two TCS, 125 CCS (mean age 40 and median age 34 years, respectively; mean follow-up time 9.2 and 24 years, respectively) and a corresponding number of age-matched controls.

Measurements

Fasting morning blood samples were analyzed for total testosterone (TT), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The odds ratios (OR) for hypogonadism, defined as either primary, secondary, compensated or ongoing androgen replacement, were calculated for TCS and CCS, and for subgroups defined by diagnosis and treatment.

Results

Hypogonadism was found in 26% of CCS and 36% of TCS, respectively (OR: 2.1, p=0.025 and OR=2.3, p=0.021). Among CCS, the OR was further increased in those given testicular irradiation (OR=28, p=0.004). Radiotherapy other than cranial or testicular irradiation plus chemotherapy, or cranial irradiation without chemotherapy, associated also with increased ORs (OR=3.7, p=0.013, and OR=4.4, p=0.038, respectively). Among TCS, those receiving >4 cycles of cisplatin-based chemotherapy had OR=17, p=0.015.

Conclusions

Biochemical signs of testosterone deficiency are recognized as markers of decreased life expectancy. Thus, the risk of hypogonadism in TCS and CCS should be recognized and emphasizes the need of long-term follow-up for these men.

This article is protected by copyright. All rights reserved.

http://ift.tt/2ojDSGi